Wahab
|
2009
|
7
|
Blood
|
America
|
91
|
11
|
65
|
Unknown
|
Calculated from K-M curves
|
Unknown
|
AML
|
Nibourel
|
2010
|
6
|
Blood
|
France
|
111
|
19
|
43
|
Direct sequencing
|
Calculated from K-M curves
|
Anthracycline-cytosine arabinoside induction treatment followed by HDAC consolidation or allo-HSCT
|
AML
|
Metzeler
|
2011
|
9
|
Journal of Clinical Oncology
|
America
|
418
|
95
|
> 60
|
Direct sequencing
|
Calculated from K-M curves
|
Standard intensive therapy
|
CN-AML
|
Kosmider
|
2011
|
7
|
Haematologica
|
France
|
247
|
49
|
66
|
Direct sequencing
|
Unitivariate or calculated from K-M curves
|
Intensive chemotherapy with anthracycline-cytarabine
|
s-AML
|
Chou
|
2011
|
7
|
Blood
|
China
|
486
|
64
|
51.5
|
Unknown
|
Multivariate and calculated from K-M curves
|
Standard intensive therapy or palliativecare or low-dose chemotherapy
|
AML
|
Patel
|
2012
|
8
|
The New England Journal of Medicine
|
America
|
391
|
33
|
< 60
|
Direct sequencing
|
Calculated from K-M curves
|
Induction therapy with high or standard dose of DNR
|
AML
|
Weissmann
|
2012
|
7
|
Leukemia
|
Germany
|
318
|
87
|
66.4
|
Next-generation sequencing
|
Calculated from K-M curves
|
Unknown
|
AML
|
Gaidzik
|
2012
|
8
|
Journal of Clinical Oncology
|
Germany
|
783
|
60
|
< 60
|
Direct sequencing
|
Calculated from K-M curves
|
Double induction therapy
|
AML
|
Renneville
|
2014
|
6
|
Oncotarget
|
France
|
139
|
19
|
62
|
Direct sequencing
|
Univariate
|
Standard front-line chemotherapy with or without low-dose gemtuzumab ozogamicin
|
CN-AML
|
Damm
|
2014
|
8
|
Genes Chromosomes and Cancer
|
France and Germany
|
215
|
13
|
< 60
|
Direct sequencing
|
multivariate
|
Intensive double induction and consolidation therapy
|
CN-AML
|
Tian
|
2014
|
7
|
International Journal of Hematology
|
Asia
|
373
|
60
|
45
|
Direct sequencing
|
Calculated from K-M curves
|
Standard induction therapy followed by consolidation of HDAC or allo-HSCT
|
CN-AML
|
S.Ohgami
|
2015
|
7
|
Modern Pathology
|
America
|
93
|
6
|
55
|
Next-generation sequencing
|
Muitivariate
|
Standard induction therapy with cytarabine and danorubicin or idarubicin
|
AML
|
Ahn
|
2015
|
9
|
Haematologica
|
Multiple region
|
407
|
54
|
52
|
Direct sequencing
|
Muitivariate
|
Standard induction therapy
|
CN-AML
|
Kao
|
2015
|
8
|
Oncotarget
|
China
|
98
|
18
|
55
|
Direct sequencing
|
Calculated from K-M curves
|
Standard intensive therapy with daunomycin and cytarabine
|
AML with MLL-PTD
|
Cher
|
2016
|
8
|
Blood Cancer Journal
|
China
|
96
|
8
|
41
|
Next-generation sequencing
|
Multivariate and univariate
|
Induction chemotherapy comprising cytarabine and daunorubicin with consolidation therapy comprising HDAC or allo-HSCT
|
CBF-AML
|
Lin
|
2016
|
9
|
Cancer Medicine
|
China
|
112
|
12
|
42.6
|
Next-generation sequencing
|
Multivariate
|
Standard therapy with or without allo-HSCT
|
AML
|